drugset / Trial / NCT00562055

Double-Blind, Four Week Trial Of [S,S]-Reboxetine And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.

NCT00562055

Phase 2 Withdrawn Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will compare the safety and efficacy of \[S,S\]-reboxetine to atomoxetine in the treatment of adult patients with attention deficity-hyperactivity disorder.

Timeline

Start
2007-11
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atomoxetine Other / unclassified
Subject [S,S]-Reboxetine Unknown